France expert in the treatment of bone metastases of breast cancer progress

France national health and medical sciences 21, announces that the experts found that currently used for the prevention of breast cancer patients with osteoporosis drugs double phosphate compounds not only inhibits the ability of osteoclasts, and can suppress tumor cells. This discovery will help to improve the treatment of bone metastases of breast cancer.

As a result of breast cancer cells easily through the lymphatic system and circulatory system, and some breast cancer patients with bone metastases occur frequently. Under normal conditions, the human body of osteoclasts and osteoblasts and always maintain a balance, but in the event of a bone metastases, osteoclasts are cells stimulate the hyperactive, causing or fractures in patients with osteoporosis. To do this, the doctor usually let patients taking two phosphate compounds, prevention of the disease.

France national health and medical sciences cleja Ding-led research team found in animal experiments, double phosphate compounds can directly act on bone cancer cells, but the dose must be present to prevent fractures in doses of 10 to 40 times to be effective, but disposable high-dose has loss of kidney function.

To this end, researchers on various drugs and per-use dose and interval for further study. Results found that, in all double phosphate compounds, zoledronic acid salt inhibits tumor cells works best, if suffering from bone cancer every day in experimental animal injection of a certain dose of zoledronic acid salts, their tumors shrink 88%.

Researchers believe that a large number of experiments that often low-dose administration of phosphorylated compounds can increase-in the blood concentrations of such substances, thereby inhibiting tumor cells; on the contrary, large doses and longer to use intervals such drugs exert pressure not only to the kidney, and is very easy to be expelled from the body, the blood in this drug content cannot achieve the desired concentration.

France national health and Medical Research Institute, the incidence of breast cancer and bone metastases is very high, this research has brought the Gospel to patients, but due to the dual effect of phosphate compounds and the use of the dose and frequency has a direct relationship, therefore, must be further explored in clinical drug use.